Immunization with DNA Vaccine Expressing Herpes Simplex Virus Type 1 gD and IL-21 Protects against Mouse Herpes Keratitis

The development of novel vaccines to eradicate herpes simplex virus (HSV) is a global public health priority. In this study, we developed a DNA vaccine expressing HSV-1 glycoprotein D (gD) and mouse interleukin-21(IL-21) and intramuscularly inoculated mice 3 times at 2-week intervals with a total of...

Full description

Saved in:
Bibliographic Details
Published in:Immunological investigations 2011, Vol.40 (3), p.265-278
Main Authors: Hu, Kai, He, Xiangfeng, Yu, Fangliu, Yuan, Xianwen, Hu, Weihua, Liu, Chunsheng, Zhao, Fengshu, Dou, Jun
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral - blood
Cercopithecus aethiops
Cytokines - blood
DNA Vaccine
Female
Glycoprotein D
Herpes Keratitis
Herpes simplex virus type 1
Immunity, Cellular - immunology
Interleukin-21
Interleukins - genetics
Interleukins - immunology
Keratitis, Herpetic - pathology
Keratitis, Herpetic - prevention & control
Mice
Mice, Inbred BALB C
Vaccination
Vaccines, DNA - genetics
Vaccines, DNA - immunology
Vero Cells
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - genetics
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of novel vaccines to eradicate herpes simplex virus (HSV) is a global public health priority. In this study, we developed a DNA vaccine expressing HSV-1 glycoprotein D (gD) and mouse interleukin-21(IL-21) and intramuscularly inoculated mice 3 times at 2-week intervals with a total of 300 μg mouse. Two weeks after the last immunization the specific antibody, splenocyte proliferative response to gD, IFN-γ and IL-4 as well as the cytotoxic activities of splenocytes and natural killer (NK) cells were assayed. Immune protection against herpes keratitis was concurrently evaluated in the immunized mice after HSV-1 challenge of the mouse cornea. The results showed that the DNA vaccine pRSC-gD-IL-21 generated higher levels of antibody, IFN-γ and IL-4, and enhanced the splenocyte proliferative response to gD as well as the cytotoxic activity of splenocytes and NK cells to target cells compared with the response in either the pRSC-gD or mock plasmid pRSC immunized mice. Importantly, the pRSC-gD-IL-21 ameliorated herpes keratitis severity and time course after corneal infection with HSV-1. The findings suggest that the DNA vaccine pRSC-gD-IL-21 may induce an immune response that can limit HSV-1 infection and development of herpes keratitis in the immunized mice.
ISSN:0882-0139
1532-4311
DOI:10.3109/08820139.2010.534219